Pharmaceutical products for Ipratropium bromide

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen·Dresden, Germany·Deadline Sep 30, 2027 · 329 days left·Open·Supplies

Structured notice only

Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

46/100

Opportunity Score

Needs reviewHigh complexity

SuppliesOpen

Why this score?

Opportunity

46 / 100

Complexity

68 / 100

Risk factors

The notice provides no guaranteed quantity or minimum purchase volume, so expected revenue cannot be reliably forecast.

The buyer may terminate the open-house procedure early, particularly after exclusive rebate agreements are concluded; e...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

Description
Industries & Services
Capabilities
Market & Experience
Certifications

Tender facts

Contracting authority: AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Country: Germany
CPV: 33600000 - Pharmaceutical products
Deadline: Sep 30, 2027

Overview

Moderate opportunity

Key Facts

Supplies contract
1 lot
Duration until Sep 2027
Conclusion of non-exclusive pharmaceutical rebate agreements under § 130a(8) SGB V for Ipratropiumbromide medicines, ATC R03BB01.
Metered-dose inhaler dosage forms are excluded.

Show full summary

Open-house framework-style participation opportunity for pharmaceutical entrepreneurs offering Ipratropiumbromide medicines under ATC R03BB01, excluding metered-dose inhalers. Participation is open to all eligible pharmaceutical entrepreneurs accepting fixed contract terms; there is no exclusivity, no guaranteed volume, and no individual negotiation. The procurement documents and discount terms were not provided for analysis. The structured data and XML notice contain inconsistencies regarding buyer address, electronic submission wording, EU funding, and certain dates.

Risks

The notice provides no guaranteed quantity or minimum purchase volume, so expected revenue cannot be reliably forecast.

The buyer may terminate the open-house procedure early, particularly after exclusive rebate agreements are concluded; e...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

The participant must be a pharmaceutical entrepreneur within the meaning of § 4(18) AMG in relation to the offered medicines.
The pharmaceutical entrepreneur must have its seat within the scope of the AMG, another EU Member State, or another EEA contracting state, as stated in the notice.
Local representatives may participate only if they themselves qualify as pharmaceutical entrepreneurs for the offered medicines.

Requirements may be incomplete.

Buyer

Name

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen

Location

Dresden, DEU

[email protected]

Website

www.aok.de/pk/plus/

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Ipratropiumbromide pharmaceutical products under an open-house rebate agreement

Non-exclusive rebate agreement under § 130a(8) SGB V for medicines containing Ipratropiumbromide, ATC R03BB01, excluding the metered-dose inhaler dosage form. Participation is open during the participation period to pharmaceutical entrepreneurs meeting and accepting the participation requirements. Quantities are unknown and no minimum purchase volume is guaranteed.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Sep 2026 - Sep 2027